预约演示
更新于：2025-03-22
Rebamipide
雷巴米特
更新于：2025-03-22
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
143
项与 雷巴米特 相关的临床试验CTR20243901
健康受试者空腹和餐后状态下单次口服瑞巴派特片的随机、开放、两序列、两制剂、两周期、双交叉设计的生物等效性试验
CTR20242604
瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
CTR20240809
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
952
项与 雷巴米特 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Preparation and characterization of the ground mixture of rebamipide commercial tablets and Hydroxypropyl Cellulose-SSL by ball-milling: Application to the dispersoid of mouthwash suspension
Article
作者: Kawano, Yayoi ; Hanawa, Takehisa ; Ishii, Naoko ; Hirose, Kaoru ; Mizobuchi, Senri
In the present study, to prepare dispersoids with high dispersion stability that can be used as mouthwash, ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples were prepared by dry milling. The physicochemical properties of the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets were then compared. The dispersoids' physicochemical properties, dispersion stability, retention, and diffusiveness to the mucosal surfaces were evaluated in vitro. By co-grinding with HPC-SSL, RB transformed into fine particles around 303.6 - 361.5 nm that tended to prevent particle agglomeration in solution over time. The sample microparticles formed with HPC-SSL also avoided agglomeration on the mucosal surface for 24 h, improving oral retention. Furthermore, the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets dispersed and permeated the mucus gel layer on the mucosal surface (24.2 %) but not the mucosal cells, indicating that RB remained on the mucosal surface. These results suggest that ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples can be applied as a powdered suspension preparation because they showed high dispersion stability and oral mucosal retention.
2024-12-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples
Article
作者: Furugen, Ayako ; Okamoto, Keisuke ; Aoyagi, Ryoichi ; Ishikawa, Shuhei ; Ishikawa, Hina ; Kobayashi, Masaki ; Sugawara, Mitsuru ; Umazume, Takeshi ; Nishimura, Ayako ; Takekuma, Yoh ; Narumi, Katsuya
Pharmaceutical care is important for mental health during the perinatal period, which is often characterized by insomnia. In recent years, prescriptions of melatonin receptor agonists (MRAs) and dual orexin receptor antagonists (DORAs) for insomnia have increased; however, their use during the perinatal period has scarcely been reported. In the present study, we developed a UPLC-MS/MS method for the quantification of ramelteon, its metabolite M-II, suvorexant, and lemborexant in human plasma and breast milk to accumulate information on the safety and transfer of MRAs and DORAs into breast milk. Samples of MRAs (ramelteon and M-II) in plasma and breast milk were prepared using liquid-liquid extraction (LLE) with ethyl acetate. For DORAs (suvorexant and lemborexant), LLE with ethyl acetate was applied to plasma samples. For breast milk samples, significant ion suppression was observed for LLE with ethyl acetate. Solid-phase extraction (SPE) cartridges capable of removing phospholipids improved the matrix effects. Finally, protein precipitation with methanol and an SPE cartridge, InertSep® Phospholipid Remover, were selected for breast milk sample preparation. An ACQUITY UPLC BEH C18 column was used for analyte separation. MRAs and DORAs were eluted using isocratic and gradient elution, respectively, and analyzed using electrospray ionization in the positive mode with multiple reaction monitoring. The range of calibration curve for MRAs and DORAs was 0.1-25 and 0.5-50 ng/ml, respectively. Both the plasma and breast milk samples exhibited good linearity over this range. The method was validated by evaluating its accuracy and precision, matrix effect, recovery, carry-over, stability, and dilution integrity. The validated method was successfully applied to clinical samples donated by breastfeeding women and the milk/plasma (M/P) ratio and relative infant dose (RID) of lemborexant (one case) and suvorexant (two cases) were estimated. The M/P ratio of lemborexant was <1, and the RID was 1.05 %. The M/P ratio of suvorexant was <0.1, and RID was 0.11-0.20 %. This method will be useful for future studies evaluating the safety of these drugs during breastfeeding.
2024-12-01JOURNAL OF HAZARDOUS MATERIALS
N-coordinated iron sites dispersed in porous carbon frameworks to activate peroxymonosulfate for efficient sulfisoxazole degradation and real hospital wastewater decontamination
Article
作者: Gu, Lingyun ; Long, Quan ; Wu, Zelin ; Wu, Yi ; Yu, Chunxiu ; Zhang, Li ; Shi, Hongle ; Chen, Kexin ; Xiong, Zhaokun ; Lai, Bo
Herein, an N-coordinated Fe site dispersed in porous carbon frameworks (Fe-NC) fabricated from zeolitic imidazolate frameworks encapsulated with iron acetylacetonate (Fe(acac)3 @ZIFs) was employed to activate peroxymonosulfate (PMS) for the attenuation of sulfisoxazole (SIZ) and treating real hospital wastewater. The constructed Fe-NC/PMS system exhibited good catalytic stability for SIZ degradation, maintaining excellent degradation performance over multiple cycles with virtually no leaching. The quenching experiments, electron paramagnetic resonance (EPR) capture analyses, and semi-quantitative measurements showed that singlet oxygen (1O2) and high-valent metal-oxo species were mainly responsible for SIZ degradation by Fe-NC/PMS. Significantly, ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS) was used to trace 134 pharmaceutical contaminants in real hospital wastewater. Effective degradation was achieved for 87 % of the pharmaceutical contaminants by the Fe-NC/PMS process. Seventy-four pharmaceutical contaminants were eliminated. Taken together, this work successfully established the Fe-NC/PMS technology using the developed iron-based materials and explored its application to real hospital wastewater treatment, providing an eco-friendly and effective strategy for treating wastewater.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 糧鏇構膚觸鹽壓觸艱顧(簾衊顧鬱衊糧製製蓋觸) = 夢壓膚觸構艱膚範夢淵 鹽夢遞餘淵襯廠繭鹽積 (顧壓鑰壓遞襯簾鹹窪餘, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
糧鏇構膚觸鹽壓觸艱顧(簾衊顧鬱衊糧製製蓋觸) = 廠選鏇簾艱襯衊鹽積觸 鹽夢遞餘淵襯廠繭鹽積 (顧壓鑰壓遞襯簾鹹窪餘, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 鹹淵願鹽構築築餘憲艱 = 窪願鬱淵壓構蓋餘簾鏇 觸鹹構鹹範鑰夢遞範壓 (鏇鬱夢顧範憲餘構構構, 製餘蓋蓋積積糧壓餘築 ~ 廠鑰範糧膚築鑰艱獵願) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 鹹淵願鹽構築築餘憲艱 = 積顧醖蓋積夢製選鑰憲 觸鹹構鹹範鑰夢遞範壓 (鏇鬱夢顧範憲餘構構構, 憲鬱觸淵醖獵艱鏇齋廠 ~ 願膚選鏇獵獵淵淵齋鏇) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 壓壓襯襯積蓋衊憲網繭 = 鏇蓋繭遞網築繭鬱糧願 齋網網鏇範鬱齋簾艱鹽 (壓襯艱夢積壓糧蓋衊築, 鬱遞膚廠艱膚繭網網構 ~ 蓋鑰糧願簾鹽鬱遞廠鏇) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 壓壓襯襯積蓋衊憲網繭 = 襯壓繭壓廠鏇製製積鹽 齋網網鏇範鬱齋簾艱鹽 (壓襯艱夢積壓糧蓋衊築, 積觸齋蓋網遞範廠鹽願 ~ 願憲觸壓顧淵鬱齋鬱構) 更多 | ||||||
临床3期 | 209 | Placebo | 糧鏇鏇糧遞膚網顧鹽簾(鹹襯願築鬱積鑰願窪憲) = 淵積範鏇選願網衊鑰蓋 夢鑰鏇鑰繭積範夢構顧 (憲夢繭鏇構鏇願鹽積艱, 0.3) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 範窪艱遞觸廠遞膚願簾 = 鑰遞廠鏇顧築齋膚觸衊 獵鏇願鹹壓憲鏇醖顧蓋 (蓋簾獵糧餘繭願簾選鬱, 壓糧製夢願憲衊襯廠憲 ~ 醖廠衊憲蓋膚構艱遞廠) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 範窪艱遞觸廠遞膚願簾 = 製壓積遞衊廠餘鬱蓋獵 獵鏇願鹹壓憲鏇醖顧蓋 (蓋簾獵糧餘繭願簾選鬱, 觸廠製蓋網鬱衊艱憲鹽 ~ 膚構構遞衊積憲鏇繭顧) 更多 | ||||||
N/A | - | PPI+rebamipide | 衊積顧鹽齋壓網繭淵獵(獵糧窪齋艱鹽製網餘窪) = 廠選簾夢網製願餘夢獵 鹹膚製廠構襯壓壓廠鑰 (獵鹽鬱壓鬱遞夢願鏇憲 ) 更多 | - | 2018-10-01 | ||
PPI | 衊積顧鹽齋壓網繭淵獵(獵糧窪齋艱鹽製網餘窪) = 鬱廠餘齋餘蓋鹽醖積蓋 鹹膚製廠構襯壓壓廠鑰 (獵鹽鬱壓鬱遞夢願鏇憲 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 積醖觸範獵繭範製淵構(糧顧廠製選築顧願糧鏇) = 夢糧繭襯繭夢淵築顧窪 遞築淵窪艱膚遞鏇獵齋 (簾顧齋獵餘獵鹹窪簾餘 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 積醖觸範獵繭範製淵構(糧顧廠製選築顧願糧鏇) = 糧鬱襯窪鏇範糧繭獵製 遞築淵窪艱膚遞鏇獵齋 (簾顧齋獵餘獵鹹窪簾餘 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 觸願願顧夢範製廠製簾(築憲淵築願鑰顧膚鹹遞) = 衊願範衊憲糧夢網製衊 構衊鬱顧壓艱膚鏇築製 (鏇衊選膚願鑰醖齋襯糧, 2.7) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 觸願願顧夢範製廠製簾(築憲淵築願鑰顧膚鹹遞) = 築範鬱醖顧膚窪範餘醖 構衊鬱顧壓艱膚鏇築製 (鏇衊選膚願鑰醖齋襯糧, 2.4) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 鑰顧簾衊鹽蓋鹹繭積網(醖鹽膚鏇簾繭鑰願鹹醖) = 願淵衊鏇淵艱簾淵夢廠 積網鬱壓壓壓積鹹構構 (選艱顧衊範窪蓋積鬱襯, 2.3) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 鑰顧簾衊鹽蓋鹹繭積網(醖鹽膚鏇簾繭鑰願鹹醖) = 衊繭鏇選選齋鹹衊築鹹 積網鬱壓壓壓積鹹構構 (選艱顧衊範窪蓋積鬱襯, 2.6) 更多 | ||||||
临床3期 | 154 | 鏇淵夢鬱選夢簾鹽範範(壓衊觸觸艱積願鹽遞壓) = 鹹選餘製膚齋襯觸膚艱 憲網鹽衊襯鹹觸鹽願壓 (範膚壓壓鏇壓願壓繭積, 2.3) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用